Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.82
-2.2%
$2.03
$1.23
$4.92
$69.81M-0.17163,342 shs192,309 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
$0.00
$0.13
$50K1.997,266 shs1,404 shs
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
$0.34
$0.17
$0.74
$18.10M0.6494,622 shs932,700 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.63
-3.9%
$0.67
$0.40
$0.94
$67.81M1.27198,148 shs135,733 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
-2.15%-2.15%-2.15%+24.66%-32.59%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%-28.57%-50.00%
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
VolitionRx Limited stock logo
VNRX
VolitionRx
-3.95%+3.14%-9.31%-3.34%-7.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.82
-2.2%
$2.03
$1.23
$4.92
$69.81M-0.17163,342 shs192,309 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
$0.00
$0.13
$50K1.997,266 shs1,404 shs
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
$0.34
$0.17
$0.74
$18.10M0.6494,622 shs932,700 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.63
-3.9%
$0.67
$0.40
$0.94
$67.81M1.27198,148 shs135,733 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
-2.15%-2.15%-2.15%+24.66%-32.59%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%-28.57%-50.00%
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
VolitionRx Limited stock logo
VNRX
VolitionRx
-3.95%+3.14%-9.31%-3.34%-7.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Metagenomi, Inc. stock logo
MGX
Metagenomi
3.00
Buy$10.00449.45% Upside
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
0.00
N/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
3.00
Buy$3.50455.38% Upside

Current Analyst Ratings Breakdown

Latest NYMX, VNRX, NAVB, and MGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
8/19/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
8/15/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$12.00 ➝ $11.00
8/15/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
8/14/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$16.00 ➝ $12.00
7/17/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
7/9/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Metagenomi, Inc. stock logo
MGX
Metagenomi
$33.77M2.02N/AN/A$6.28 per share0.29
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K6.16N/AN/AN/A
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
N/AN/AN/AN/A($0.01) per shareN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
$1.32M51.40N/AN/A($0.11) per share-5.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$78.06M-$2.36N/AN/AN/A-257.99%-37.84%-27.15%11/12/2025 (Estimated)
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18MN/A0.00N/AN/AN/AN/AN/A
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
-$6.58M-$0.04N/AN/AN/AN/A-1,589.50%-117.25%N/A
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.25N/AN/A-2,321.14%N/A-163.39%N/A

Latest NYMX, VNRX, NAVB, and MGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.68-$0.54+$0.14-$0.54$7.72 million$8.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
6.36
6.36
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
N/A
0.19
0.19
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.22
0.22

Institutional Ownership

CompanyInstitutional Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
1.14%
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
17.80%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
54.00%
VolitionRx Limited stock logo
VNRX
VolitionRx
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
23637.53 million30.85 millionN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionOptionable
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
390.51 million41.64 millionOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
80107.60 million80.80 millionOptionable

Recent News About These Companies

Volition Signs First Human Out Licensing Deal
Zacks Small Cap Estimates VolitionRx Q3 Earnings
Insights into VolitionRX's Upcoming Earnings
VolitionRx Limited (VNRX) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.82 -0.04 (-2.15%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$1.84 +0.02 (+1.37%)
As of 06:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

$0.0005 0.00 (0.00%)
As of 09/15/2025 03:55 PM Eastern

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Nymox Pharmaceutical stock logo

Nymox Pharmaceutical NASDAQ:NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

VolitionRx stock logo

VolitionRx NYSE:VNRX

$0.63 -0.03 (-3.95%)
Closing price 09/15/2025 03:59 PM Eastern
Extended Trading
$0.63 0.00 (-0.03%)
As of 09/15/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.